Business Wire

mimik Operationalizes Agentic AI on the AMD Ryzen™ AI Embedded X100 Series

23.7.2026 20:30:00 CEST | Business Wire | Press release

Share

mimik today announced mimOE™ Embedded Edition, a package of its Agentix Operating Engine and a set of purpose-built tools for the AMD Ryzen™ AI Embedded X100 Series processor, the newest processor in a family designed for physical AI, autonomous systems, and industrial automation. Available to download today, mimOE Embedded Edition gives OEMs, tier-1 suppliers, system integrators, and agent developers the path to operationalize Agentix-Native systems (aka Agentic AI), in which autonomous agents can reason, coordinate, and act directly on devices, from PoC to scaled operations with certainty.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260723555565/en/

Agentic AI operations are both CPU and GPU bound. Enterprises can now scale with certainty.

Generative AI has centered on the GPU. Agentix-Native systems must spread the work. In a real multi-agent workflow traced by mimik, more than 80 percent of operations were CPU work: discovery, inter-agent collaboration, security, data movement, routing, and lifecycle management. Under 20 percent were model inference on the GPU.

The other major benefit is memory efficiency. mimOE loads shared models once and references them across agents and tenants, so multi-tenant workloads that exceed any current device’s memory under conventional deployment fit comfortably on one X100 Series processor: more agents and more tenants per device, without adding silicon.

mimOE Embedded Edition brings multi-agent choreography, zero-trust security, dynamic service discovery, continued operation through network disruption, and multi-cloud integration as per workflow needs and operator choice, all engine properties rather than custom integration.

The benefits for OEMs and tier-1 suppliers are design wins that reach production instead of stalling at PoC. For system integrators, repeatable delivery across programs. For enterprises, scaled Agentix-Native operations with certainty on compute they already own. For developers, one agentic operating environment from end devices to the cloud.

“The industry has solved intelligence. It has not solved operationalization, and the tools we use in the cloud today do not fit Agentix-Native systems. These are living systems that behave differently by nature; you cannot bolt existing tooling onto them,” said Sam Armani, Senior Vice President of Business Development at mimik. “That is why mimOE and the tools around it are purpose-built for the Agentix era. We run on it ourselves, every day; that is how we move fast and stay flexible as we scale.”

“Agentic AI is shifting compute toward workloads that exercise the CPU, GPU, and NPU together. The AMD Ryzen AI Embedded portfolio was designed for that balance, and with mimik's mimOE running on the platform, our customers can run more agents on the same device and serve more of their own customers per deployment, moving from design-in to production Agentix-Native deployments faster,” said Yousef Khalilollahi, Corporate Vice President and General Manager, AMD.

mimOE Embedded Edition and the Agentix Benchmarking tools are part of mimik’s Agentix-Native toolset. Download the benchmarking tool for the AMD X100 Series processor at (https://www.mimik.com/mimoe-studio-features/benchmark). Choose the type of AI model suited to each workflow and start running Agentix-Native systems today. The three technical studies behind this announcement are here (https://www.mimik.com/agentix-compute-benchmarking). Contact us for a demo or additional questions (https://www.mimik.com/contact-us).

About mimik

mimik is an Agentix-Native company, a pioneer in Device-First Continuum AI and Compute. mimik's software platform is the operating engine for enterprises and developers to scale Agentix-Native systems with certainty, with full flexibility, on their own terms. The company has partnered with major chip vendors, device OEMs, cloud providers, and system integrators, working closely with them to enable fast-track, scaled delivery of AI to organizations in manufacturing, healthcare, transportation, retail, smart buildings, and physical AI more broadly. The outcome is business efficiency across multiple dimensions.

mimOE, Agentix Operating Engine, and Device-First Continuum AI & Compute are trademarks ofmimik Technology Inc. AMD, the AMD arrow logo, Ryzen, and combinations thereof are trademarks of Advanced Micro Devices, Inc. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260723555565/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye